RecruitingPhase 3NCT06774131
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
Sponsor
UroGen Pharma Ltd.
Enrollment
70 participants
Start Date
Aug 6, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \[mitomycin\] for pyelocalyceal solution), instilled in the upper urinary tract (UUT) of patients with low-grade upper tract urothelial cancer (LG-UTUC).
Eligibility
Min Age: 18 Years
Inclusion Criteria22
- Provide written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and protocol.
- Naive or recurrent patients with LG, non-invasive UTUC in the pyelocalyceal system, with the following disease characteristics:
- At least 1 measurable papillary LG tumor, evaluated visually, ≤ 15 mm. The largest lesion should not exceed 15 mm. Debulking to ≤ 15 mm is permitted.
- Biopsy taken from at least 1 tumor located above the ureteropelvic junction revealing LG urothelial carcinoma (UC). Patients who have been biopsied within 8 weeks before Screening for this study and shown to have LG UC may have these historical biopsies used for enrollment into the study and do not require repeat biopsy during Screening.
- Patient should have at least 1 remaining papillary LG tumor evaluated visually with a diameter of at least 5 mm post-biopsy.
- Wash urine cytology sampled from the pyelocalyceal system documenting the absence of high-grade (HG) UC, diagnosed not more than 8 weeks before Screening.
- Patients with Eastern Cooperative Oncology Group (ECOG) performance status < 3 (with Karnofsky > 40).
- Patients with life expectancy > 24 months at time of Screening.
- Patients must have adequate organ and bone marrow function as determined by the following routine laboratory tests:
- Leukocytes ≥ 3,000/μL (≥ 3 × 10\^9/L).
- Absolute neutrophil count ≥ 1,500/μL (≥ 1.5 × 10\^9/L).
- Platelets ≥ 100,000/μL (≥ 100 × 10\^9/L).
- Hemoglobin ≥ 9.0 g/dL.
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN).
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN.
- Alkaline phosphatase ≤ 2.5 × ULN.
- Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min.
- Patient has no active urinary tract infection (UTI) as confirmed by urine culture or urinalysis. Note: In case of a symptomatic UTI the patient will be treated with antibiotics and the instillation will be postponed until resolution. In the case of asymptomatic bacteriuria, the use of prophylactic antibiotics and postponement of treatment is at the discretion of the investigator.
- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for clinical study participants.
- Female patients of childbearing potential (defined as premenopausal women who have not been sterilized) and male patients with female partners of childbearing potential must agree to use 2 acceptable forms of effective contraception from enrollment through 6 months post treatment. Sexually active male patients must agree to use a condom during intercourse for at least 48 hours after each instillation.
- Acceptable methods of birth control considered to have a low failure rate (ie, less than 1% per year) when used consistently and correctly include implants, injectable, combined (estrogen/progesterone) oral contraceptives, intrauterine devices (only hormonal), condoms with spermicide, sexual abstinence* or vasectomized partner.
- * Sexual abstinence is defined as refraining from intercourse from enrollment through 6 months post treatment. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is NOT an acceptable method of contraception.
Exclusion Criteria19
- UC specific exclusions:
- Patient received Bacillus Calmette-Guérin (BCG) treatment for UC during the 6 months before enrollment.
- The patient has untreated concurrent UC in locations other than the target area (unless treated and resolved during Screening); ie, ureteral and lower urinary tract tumors must be completely ablated before entry.
- Patient has a history of carcinoma in situ (CIS) in the urinary tract.
- Patient has a history of invasive UC in the past 5 years.
- Patient has a history of HG papillary UC in the urinary tract in the past 2 years.
- Patient is actively being treated or intends to be treated with systemic chemotherapy during the duration of the study.
- Any other malignancy diagnosed within 2 years before enrollment with the exception of:
- Basal or squamous cell skin cancers.
- Noninvasive cancer of the cervix.
- Any other cancer deemed to be of low risk for progression or patient morbidity during the study period in the opinion of the investigator.
- Patient with urinary obstruction such that there is an inability to deliver the study treatment to the pyelocalyceal system either via ureteral catheter (retrograde administration) or nephrostomy tube (antegrade administration).
- Known allergy or sensitivity to any component of the study treatment (including excipients) that in the investigator's opinion cannot be readily managed.
- Patient has an intractable bleeding disorder (eg, coagulation factors deficiencies, Von Willebrand disease).
- Patient is currently receiving any other investigational product, has participated in a research protocol involving administration of an investigational product in the past 30 days, or plans to participate in a research protocol involving administration of an investigational product during study conduct.
- Patient was previously treated with JELMYTO (product code UGN-101) for UTUC.
- Women who are pregnant (positive urine or serum pregnancy test), planning to become pregnant during the study period, or who are breastfeeding are not eligible to enroll.
- Patient has any other medical or mental condition(s) that make(s) his/her participation in the study unadvisable in the opinion of the investigator.
- Where applicable per country regulation, the patient must not be currently committed to an institution by virtue of an order issued by either judicial or administrative authorities.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGUGN-104
UGN-104 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-104 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the UUT.
Locations(52)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06774131
Related Trials
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
NCT072417936 locations
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
NCT066827281 location
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
NCT0556283028 locations
Bladder Cancer Screening Trial
NCT056464851 location
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
NCT058891954 locations